Evidence map›Paper›PMID 40124332›Full record

ArticleMaterials today. Bio2025

Chondroitin sulfate nanoparticles based on co-delivery dual drug induced ferroptosis in lung cancer cells by disrupting mitochondrial oxidative homeostasis.

He Wang, Shuimu Lin, Jiacui Xie, Xuming Chen, Yating Deng, Pei Huang, Kanglong Peng, Wenhui Gao, Guodong Ye, Guihua Wang and 4 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. [SENP1 reduces ferroptosis of thyroid cancer cells by regulating hypoxia-inducible factor-1α].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

He WangThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Shuimu LinThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Jiacui XieThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Xuming ChenThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Yating DengThe Second Affiliated Hospital, Guangzhou Medical University, Guangdong, 510260 Guangzhou, People's Republic of China.
Pei HuangThe Second Affiliated Hospital, Guangzhou Medical University, Guangdong, 510260 Guangzhou, People's Republic of China.
Kanglong PengGuangdong Yuewei Pharmaceutical Co., LTD, Guangdong, 515422 Jieyang, People's Republic of China.
Wenhui GaoAffiliated Cancer Hospital and Institue of Guangzhou Medical University, Guangdong, 510350 Guangzhou, People's Republic of China.
Guodong YeThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Guihua WangJiangzhong Pharmaceutical Co., LTD, Jiangxi, 330001 Nanchan, People's Republic of China.
Xiyong YuThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Huaying WenThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.
Linghao QinSchool of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, People's Republic of China.
Yi ZhouThe Fifth Affiliated Hospital, Key Laboratory of Molecular Target and Clinical Pharmacology and the State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangdong 511436 Guangzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial REDOX homeostasis is unbalanced by large amounts of reactive oxygen species production and reduced glutathione, leading to lipid oxidation-induced ferroptosis, which enhanced cancer immunotherapy. Thus, disrupting mitochondrial redox homeostasis represents a promising strategy for the treatment of lung cancer. In this study, a co-delivery system of based on chondroitin sulfate (CS) (CS-CA-CUR-TPP, CCCT) for natural medicines (Curcumin, CUR; and Cinnamaldehyde CA) was successfully constructed, which resulted in elevated ROS levels in cancer cells. Under the action of CS specifically targeting tumor cells, CCCT NPs is enriched and taken up by lung cancer cells. Acid responsiveness causes the CCCT NPs to break and escape from the lysosome, and CUR targets and destroys mitochondria under the action of mitochondrial target head triphenylphosphine (TPP). CA collaborates with CUR to produce large amounts of ROS and reduce GSH in a time-dependent manner in mitochondria for disruption of REDOX homeostasis, and triggers ferroptosis by reducing the expression of GXP4 and xCT proteins. The immunogenic cell death (ICD) after ferroptosis promotes interferon γ (IFN-γ), TNF-a, and IL-6 secretion. Our results desmontrat CCCT can promote inhibition of tumor growth by enhancing tumor immunogenicity. This study may provide a potential avenue for the advancement of self-delivery nanoparticles to overcome resistance to apoptosis in tumor therapy.

Indexed as

Chondroitin sulfateCinnamaldehydeCurcuminFerroptosisMitochondrial REDOX homeostasis

Identifiers

PMID40124332
PMCPMC11930224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.